EFCCA is involved in this exciting project that will identify digital endpoints that provide reliable, objective and sensitive evaluation of activities of daily living and Health-related quality of life (HRQoL) in ImmuneMediated Inflammatory Diseases such as IBD as well as other such as Rheumatoid Arthritis and Lupus and which will ultimately have a positive impact on the quality of life of these patients.
Background
October, 2022
There is a high variability of out-of-packet patient costs of inflammatory bowel diseases (IBDs), but the issue is not widely recognised. Therefore, the study compared patient costs of IBDs between 12 European countries.
Transitioning through paediatric and into adult care is a critical time for patients and, if not carried out effectively and appropriately, can impact on education, mental health and patient outcomes. It has become clear that this is a major issue for patients, their carers and clinicians and that the transition process within and across Europe urgently needs reform.
The European Crohn’s and Colitis Organisation [ECCO] produces and regularly updates several guidelines to provide evidence-based guidance on critical aspects of IBD care to all health care professionals who manage patients with IBD.
READ MORE
What are the unmet needs and most relevant treatment outcomes according to patients with inflammatory bowel disease? A qualitative patient preference study
July, 2022 The study showed a high relevance of the indirect cost of IBD in the context of economic evaluation, as well as a between-country variability of work-related impairment or informal care.
Indirect Costs of Inflammatory Bowel Diseases
May, 2021
Heterogeneity exists in reported outcomes and outcome measurement instruments (OMI) from observational studies. A core outcome set (COS) for observational and real-world evidence (RWE) in inflammatory bowel disease (IBD) will facilitate pooling large datasets. This systematic review, describes and classifies clinical and patient-reported outcomes, for COS development.
May, 2022
Anti-SARS-CoV-2 vaccines clinical trials did not include patients with immune-mediated conditions such as inflammatory bowel disease (IBD). The study aimed to describe the implementation of anti-SARS-CoV-2 vaccination among IBD patients, patients' concerns and side-effect profile of the anti-SARS-CoV-2 vaccines using real-world data.